相关实验视频

Updated: Jun 16, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

在晚期黑色素瘤中,尼沃卢马布加上relatlimab:RELATIVITY-047 4年更新

Evan J Lipson¹, F Stephen Hodi², Hussein Tawbi³

¹The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.

European journal of cancer (Oxford, England : 1990)

|June 13, 2025

概括

尼沃卢马布加上relatlimab在四年后,在晚期黑色素瘤患者中显示出持久的无进展生存益处. 与单独使用尼沃卢马布相比,这种联合治疗提供了更好的结果,具有较低的毒性概况.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
黑色素瘤研究黑色素瘤研究

背景情况:

晚期黑色素瘤在治疗方面存在重大挑战.
尼沃卢马布加上relatlimab是一种试验性免疫疗法组合.
以前的研究表明,这种组合可能有好处.

研究的目的:

从RELATIVITY-047试验中提供最新的4年有效性和安全性数据.
评估nivolumab加relatlimab治疗的长期结果与晚期黑色素瘤的nivolumab单一治疗.

主要方法:

第2/3期随机试验 (相对性-047).
患者接受了尼沃卢马布480毫克加上relatlimab 160毫克固定剂量组合或尼沃卢马布480毫克静脉注射每4周一次.
主要终点:通过盲目独立中央审查 (BICR) 的无进展生存率 (PFS).
二级终点包括整体生存率 (OS) 和黑色素瘤特异性生存率 (MSS).

主要成果:

组合治疗的四年PFS率为30.6%,单独服用尼沃卢马布的比率为23.6%.
组合治疗的四年生存率为52.0%,而尼沃卢马布的42.8%.
该组合的客观响应率 (ORR) 为43.9%,而尼沃卢马布的33.4%.
结合剂的四年MSS率为59.7%,与尼沃卢马布的49.6%相比.
效率有利于大多数子组的组合,没有新的安全信号.

结论:

尼沃卢马布加上relatlimab在4年后在以前未经治疗的晚期黑色素瘤患者中显示了PFS,OS和ORR的持久改善.
与其他免疫瘤学组合相比,组合疗法提供了有利的益处风险概况,毒性较低.
长期数据支持nivolumab加relatlimab作为高级黑色素瘤的有价值的治疗选择.

关键词:

晚期的黑色素瘤是什么免疫治疗是一种免疫疗法.长期生存率长期生存率尼沃卢马布的使用情况有关可能的关系.

更多相关视频

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Skin Cancer

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...